Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of HCP1306, RLD2302 and RLD2102 in Healthy Volunteers
NCT06518122Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rosuvastatin and ezetimibe in hypercholesterolemia and dyslipidemia (7 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Curve over the dosing interval and Maximum Steady State Concentration. Started Sep 2024; status: completed.
02
Drugs
rosuvastatinezetimibe
03
Conditions
hypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on NCT06518122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06518122.